Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 10, 131
eCollection

Hereditary Spastic Paraplegia Is a Common Phenotypic Finding in ARG1 Deficiency, P5CS Deficiency and HHH Syndrome: Three Inborn Errors of Metabolism Caused by Alteration of an Interconnected Pathway of Glutamate and Urea Cycle Metabolism

Affiliations
Review

Hereditary Spastic Paraplegia Is a Common Phenotypic Finding in ARG1 Deficiency, P5CS Deficiency and HHH Syndrome: Three Inborn Errors of Metabolism Caused by Alteration of an Interconnected Pathway of Glutamate and Urea Cycle Metabolism

Emanuele Panza et al. Front Neurol.

Abstract

Hereditary Spastic Paraplegias (HSPs) are a clinically and genetically heterogeneous group of neurodegenerative disorders characterized by a progressive rigidity and weakness of the lower limbs, caused by pyramidal tract lesions. As of today, 80 different forms of HSP have been mapped, 64 genes have been cloned, and new forms are constantly being described. HSPs represent an intensively studied field, and the functional understanding of the biochemical and molecular pathogenetic pathways are starting to be elucidated. Recently, dominant and recessive mutations in the ALDH18A1 gene resulting in the deficiency of the encoded enzyme (delta-1-pyrroline-5-carboxylate synthase, P5CS) have been pathogenetically linked to HSP. P5CS is a critical enzyme in the conversion of glutamate to pyrroline-5-carboxylate, an intermediate that enters in the proline biosynthesis and that is connected with the urea cycle. Interestingly, two urea cycle disorders, Argininemia and Hyperornithinemia-Hyperammonemia-Homocitrullinuria syndrome, are clinically characterized by highly penetrant spastic paraplegia. These three diseases represent a peculiar group of HSPs caused by Inborn Errors of Metabolism. Here we comment on these forms, on the common features among them and on the hypotheses for possible shared pathogenetic mechanisms causing the HSP phenotype.

Keywords: ALDH18A1; HHH syndrome; Hereditary Spastic Paraplegia; P5CS deficiency; SPG9; arginase deficiency.

Figures

Figure 1
Figure 1
Biochemical pathway.

Similar articles

See all similar articles

Cited by 1 PubMed Central articles

References

    1. Fink JK. Advances in the hereditary spastic paraplegias. Exp Neurol. (2003) 184 (Suppl. 1):S106–10. 10.1016/j.expneurol.2003.08.005 - DOI - PubMed
    1. Fink JK. Hereditary spastic paraplegia: clinical principles and genetic advances. Semin Neurol. (2014) 34:293–305. 10.1055/s-0034-1386767 - DOI - PubMed
    1. Morais S, Raymond L, Mairey M, Coutinho P, Brandão E, Ribeiro P, et al. . Massive sequencing of 70 genes reveals a myriad of missing genes or mechanisms to be uncovered in hereditary spastic paraplegias. Eur J Hum Genet. (2017) 25:1217–28. 10.1038/ejhg.2017.124 - DOI - PMC - PubMed
    1. De Souza PVS, Bortholin T, Naylor FGM, Chieia MAT, de Rezende PWBV, Oliveira ASB. Motor neuron disease in inherited neurometabolic disorders. Rev Neurol. (2018) 174:115–124. 10.1016/j.neurol.2017.06.020 - DOI - PubMed
    1. Coutelier M, Goizet C, Durr A, Habarou F, Morais S, Dionne-Laporte A, et al. . Alteration of ornithine metabolism leads to dominant and recessive hereditary spastic paraplegia. Brain (2015) 138(Pt 8):2191–05. 10.1093/brain/awv143 - DOI - PMC - PubMed
Feedback